[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340965-105":59,"doc-detail-340965-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","treatment-of-bone-metastases-from-solid-tumors-with-bone-modifying-agents-a-web-survey-of-italian-oncologists-investigating-patterns-of-practice-drug-prescription-and-prevention-of-side-effects","Treatment of bone metastases from solid tumors with bone-modifying agents - a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects","","Optimal use of bone-modifying agents (BMAs) for bone metastases from solid tumors remains uncertain regarding drug selection, planned treatment duration and long-term regimens, and prevention or management of adverse effects such as renal toxicity, hypocalcaemia, and medication-related osteonecrosis of the jaw (MRONJ). A 24-question web survey collected responses from 191 Italian oncologists. Most prescribe BMAs at diagnosis, but hypocalcaemia prevention and long-term scheduling remain areas of uncertainty.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treatment-of-bone-metastases-from-solid-tumors-with-bone-modifying-agents-a-web-survey-of-italian-oncologists-investigating-patterns-of-practice-drug-prescription-and-prevention-of-side-effects/340965/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treatment-of-bone-metastases-from-solid-tumors-with-bone-modifying-agents-a-web-survey-of-italian-oncologists-investigating-patterns-of-practice-drug-prescription-and-prevention-of-side-effects/340965.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main purpose of the web survey?","Question",{"text":113,"@type":114},"To assess Italian oncologists’ patterns of prescribing bone-modifying agents (BMAs) for bone metastases from solid tumors, including approaches to drug choice, treatment duration, and prevention or management of side effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the survey responses collected and how many oncologists participated?",{"text":118,"@type":114},"Italian oncologists were invited by email to complete an anonymous 24-question web survey between November 2020 and January 2021. Answers from 191 oncologists were collected.",{"name":120,"@type":111,"acceptedAnswer":121},"Which factors influenced the choice between bisphosphonates and denosumab?",{"text":122,"@type":114},"Reported factors included creatinine level (32.3%), availability of patient venous access (15.8%), and type of primary neoplasm (13.6%).",{"name":124,"@type":111,"acceptedAnswer":125},"What did the survey find regarding side-effect prevention?",{"text":126,"@type":114},"Oncologists reported good confidence in measures aimed at preventing MRONJ, while uncertainty was reported for prevention and management of hypocalcaemia.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},340965,1790955048,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Supportive Care in Cancer (2024) 32:202  \n[https://doi.org/10.1007/s00520-024-08392-8](https://doi.org/10.1007/s00520-024-08392-8)  \nTreatment of bone metastases from solid tumors with bone‑modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects  \nVittorio Fusco1,2 · Massimo Di Maio3 · Anna AmelaValsecchi3 · Daniele Santini4 · Marcello Tucci5 · Ugo De Giorgi6 · Paolo Bossi7,13 · Toni Ibrahim8,14 · Luigi Cavanna9,15 · Gaetano Lanzetta10,16 · Maura Rossi1 · Giorgia Rossetti1 · Mario Airoldi11 · Alessandro Comandone11 · Saverio Cinieri12  \nReceived: 8 May 2023 / Accepted: 16 February 2024 / Published online: 1 March 2024 © The Author(s) 2024  \nAbstract  \nPurpose Optimal use of bone-modifying agents (BMAs) in patients with bone metastases from solid tumors is uncertain in some aspects: the drug choice; the planned treatment duration and long-term therapy; the prevention and management of possible side effects, including renal toxicity, hypocalcaemia, and medication-related osteonecrosis of the jaw (MRONJ) . Methods Italian oncologists were invited to fulfil a 24-question web survey about prescription of BMAs for bone metastases of breast cancer, prostate cancer, and other solid tumors. Prevention and management of side effects were also investigated. Results Answers of 191 oncologists were collected. BMAs are usually prescribed at the time of diagnosis of bone metastases by 87.0%(breast cancer) and 76.1%(solid tumors except breast and prostate cancers) of oncologists; the decision is more articulated for prostate cancer (endocrine-sensitive versus castration-resistant). The creatinine level (32.3%), the availability of patient venous access (15.8%), and the type of primary neoplasm (13.6%) are the most reported factors involved in choice between bisphosphonates and denosumab. Zoledronic acid every 3 months was considered as a valid alternative to monthly administration by 94% of Italian oncologists. Oncologists reported a good confidence with measures aimed to prevent MRONJ, whereas uncertainness about prevention and management of hypocalcemia was registered.  \nConclusion Italian oncologists showed a high attitude in prescribing bisphosphonates or denosumab at the time of diagnosis of bone metastases, with a large application of preventive measures of side effects. Further studies are needed to investigate some controversial aspects, such as optimal drug treatment duration and long-term drug schedules.  \nKeywords Bone metastases · Bone-modifying agents · Bisphosphonates · Denosumab · Survey · Osteonecrosis  \nIntroduction  \nBone is a frequent site of metastases in patients with solid tumors (breast, prostate, lung, renal, and other cancers) [1] . Bone-modifying agents (BMAs), also known as bone-targeted agents or antiresorptive drugs, include bisphosphonates and denosumab; they are largely recommended and administered to prevent skeletal-related events (SREs) inpatients with cancer metastatic to the bone [2] .  \nInternational recommendations and guidelines were delivered regarding BMA treatment in bone metastatic cancer disease and the management of BMA side effects [3–7] . In Italy, national guidelines are periodically published in  \nExtended author information available on the last page of the article  \nItalian language by AIOM (Italian Association of Medical Oncology) on the treatment of bone metastases and care of bone health in cancer patients [8] . Detailed recommendations for the prevention and management of medicationrelated osteonecrosis of the jaw (MRONJ), the main side effect of BMAs, were released by the Italian Societies of Maxillofacial Surgery (SICMF) and Oral Medicine (SIPMO) and endorsed by AIOM and other Italian scientific bodies [9] .  \nGuidelines and recommendations show some heterogeneity and uncertainty about the choice of treatment drug (bisphosphonates versus denosumab), optimal treatment duration (one versus 2 years or indefin","cbCaibKt9yB7FyHZ","https://ap.wps.com/l/cbCaibKt9yB7FyHZ","pdf",654472,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods","[{\"question\":\"What was the main purpose of the web survey?\",\"answer\":\"To assess Italian oncologists’ patterns of prescribing bone-modifying agents (BMAs) for bone metastases from solid tumors, including approaches to drug choice, treatment duration, and prevention or management of side effects.\"},{\"question\":\"How were the survey responses collected and how many oncologists participated?\",\"answer\":\"Italian oncologists were invited by email to complete an anonymous 24-question web survey between November 2020 and January 2021. Answers from 191 oncologists were collected.\"},{\"question\":\"Which factors influenced the choice between bisphosphonates and denosumab?\",\"answer\":\"Reported factors included creatinine level (32.3%), availability of patient venous access (15.8%), and type of primary neoplasm (13.6%).\"},{\"question\":\"What did the survey find regarding side-effect prevention?\",\"answer\":\"Oncologists reported good confidence in measures aimed at preventing MRONJ, while uncertainty was reported for prevention and management of hypocalcaemia.\"}]","Treatment of bone metastases from solid tumors with bone-modifying agents - a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects | PDF",1790039730,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d60c1c93b553e962a995d1e40605fd01.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b583561ee16b4e6e47c550ce2797fc63.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9642fd45e3a4f1c8f875f8194c8d9fba.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ab2962ad056773fef9232094f909854.webp",980,1301]